Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.17 Million CNY | 1894.92% |
| 2022 | 59 Thousand CNY | -91.13% |
| 2021 | 665 Thousand CNY | -46.2% |
| 2020 | 1.23 Million CNY | 186.77% |
| 2019 | 431 Thousand CNY | 0.0% |
| 2018 | - CNY | 0.0% |
| 2017 | - CNY | -100.0% |
| 2016 | 350 Thousand CNY | -63.16% |
| 2015 | 950 Thousand CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - CNY | 0.0% |
| 2024 Q2 | - CNY | 0.0% |
| 2023 Q4 | 1.17 Million CNY | 0.0% |
| 2023 Q2 | - CNY | 0.0% |
| 2023 Q3 | - CNY | 0.0% |
| 2023 Q1 | - CNY | -100.0% |
| 2023 FY | 1.17 Million CNY | 1894.92% |
| 2022 Q1 | - CNY | -100.0% |
| 2022 FY | 59 Thousand CNY | -91.13% |
| 2022 Q4 | 59 Thousand CNY | 0.0% |
| 2022 Q3 | - CNY | -100.0% |
| 2022 Q2 | 128 Thousand CNY | 0.0% |
| 2021 Q2 | 857 Thousand CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 FY | 665 Thousand CNY | -46.2% |
| 2021 Q4 | 665 Thousand CNY | 0.0% |
| 2020 Q4 | 1.23 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 1.23 Million CNY | 186.77% |
| 2020 Q2 | - CNY | 0.0% |
| 2019 Q2 | 228 Thousand CNY | 0.0% |
| 2019 Q4 | 431 Thousand CNY | 0.0% |
| 2019 FY | 431 Thousand CNY | 0.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2017 FY | - CNY | -100.0% |
| 2016 FY | 350 Thousand CNY | -63.16% |
| 2015 FY | 950 Thousand CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | 43.222% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 99.881% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 98.995% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 99.574% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | 98.334% |
| Essex Bio-Technology Limited | 36.05 Million HKD | 96.736% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | 90.805% |
| PuraPharm Corporation Limited | 81.09 Million HKD | 98.549% |
| SSY Group Limited | 1.94 Billion HKD | 99.94% |
| JBM (Healthcare) Limited | 43.8 Million HKD | 97.313% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 99.801% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.993% |